# Atlas

> Atlas provides FDA inspection and enforcement intelligence for quality and regulatory teams at pharma and medical device companies.

Use this file as a curated map of Atlas: what it covers, the public FDA inspection data pages, the analytics dashboards, the marketing pages, and all published blog posts.

## What Atlas covers
- FDA inspections since 2010, Form 483s and Establishment Inspection Reports (EIRs), FDA warning letters since 2008, and searchable inspectional observations indexed by investigator, CFR citation, and keyword.
- International agencies: MHRA (UK), PMDA (Japan), Health Canada, CDSCO (India), and Swissmedic.
- Also covers import alerts, recalls, debarment letters, and complete response letters.
- Each FDA investigator, inspected facility, and Form 483 has its own public page under /inspection-intelligence.

## Inspection Intelligence (public data)
- [FDA Inspection Database](https://www.atlas-compliance.ai/inspection-intelligence): Search FDA investigators, inspected facilities, and Form 483s, with the links between them mapped.
- [FDA Form 483 Database](https://www.atlas-compliance.ai/inspection-intelligence/form-483s): Form 483 records by company, facility, investigator, product area, and year, with the observations and the regulations cited.
- [FDA Investigator Lookup](https://www.atlas-compliance.ai/inspection-intelligence/investigators): Each FDA investigator's inspection history, the facilities they inspected, the Form 483 observations they issued, and their co-investigators.
- [FDA Facility Lookup](https://www.atlas-compliance.ai/inspection-intelligence/sites): Inspection history, outcomes, and Form 483s for FDA-inspected facilities, searchable by company name or city.

## Analytics dashboards
- [Atlas Analytics](https://www.atlas-compliance.ai/analytics): Interactive dashboards on FDA and international inspection trends.
- [US FDA Inspections Analytics](https://www.atlas-compliance.ai/analytics/us-fda-inspections-analytics): Contains inspection count vs year charts classified by country and action indicated, inspection count vs category chart and pie chart of top 10 CFR citations.
- [INDIA - Human Drugs - Trends](https://www.atlas-compliance.ai/analytics/india-human-drugs-trends): The recent CFR trends of fda inspections in India under category Human Drugs
- [Region Wise Top Issues](https://www.atlas-compliance.ai/analytics/region-wise-top-issues): The issues reported in US FDA inspections for following regions: NA (North America), LA (Latin America), EMEA (Europe, Middle East and Africa), APAC (Asia-Pacific)
- [Most Prevalent CFRs by GXP and Industry](https://www.atlas-compliance.ai/analytics/most-prevalent-cfrs-by-gxp-and-industry): Most prevalent CFRs by GXP and Industry - Year by Year comparison
- [EMA Annual Report](https://www.atlas-compliance.ai/analytics/ema-annual-report): EMA Annual report of the Good Clinical Practice Inspectors Working Group
- [Health Canada Inspections Report](https://www.atlas-compliance.ai/analytics/health-canada-inspections-report): Health Canada Inspections and Citations - Year by Year Comparison
- [Complete Response Letter (CRL)](https://www.atlas-compliance.ai/analytics/complete-response-letter-crl): CRL Analytics by Applicant Type, Approval Center and Categories
- [Average Observations per Inspection](https://www.atlas-compliance.ai/analytics/average-observations-per-inspection): Analytics for calculating average observations for a given time frame and category
- [Most Prevalent ISO Clauses by Industry](https://www.atlas-compliance.ai/analytics/most-prevalent-iso-clauses-by-industry): Shows annual trends in the most prevalent ISO 13485:2016 clauses by industry and inspection classification (NAI, VAI, OAI)

## Marketing
- [Homepage](https://www.atlas-compliance.ai/): Overview of Atlas, product positioning, and primary calls to action.
- [Product](https://www.atlas-compliance.ai/product): Core Atlas workflows, platform capabilities, and use cases.
- [About](https://www.atlas-compliance.ai/about): Company background and product context.
- [Demo](https://www.atlas-compliance.ai/demo): Primary conversion page for booking a product walkthrough.
- [Newsletter](https://www.atlas-compliance.ai/newsletter): Subscription page for Atlas compliance and inspection insights.
- [Blog](https://www.atlas-compliance.ai/blog): Archive of published Atlas articles and commentary.
- [Redica Systems alternative](https://www.atlas-compliance.ai/redica-alternative): How Atlas compares with Redica Systems on coverage, data freshness, search, and price.

## Blog Posts
- [Cleaning validation: FDA and EMA requirements, acceptance limits, and what 483s cite](https://www.atlas-compliance.ai/blog/cleaning-validation-fda-requirements): What FDA and EMA require for cleaning validation: 21 CFR 211.67 and 211.182, FDA's 1993 inspection guide, ICH Q7 section 12.7, EU GMP Annex 15 and the EMA guideline on health-based exposure limits. Covers acceptance limits (HBEL/PDE, 1/1000
- [Data integrity citations on FDA Form 483s: the sections FDA cites and how often, 2025 to 2026](https://www.atlas-compliance.ai/blog/data-integrity-fda-483-citations): What counts as a data integrity citation on an FDA Form 483, which 21 CFR sections FDA uses for it, what ALCOA and ALCOA+ mean in FDA's 2018 guidance, and how often data integrity sections appeared on 779 human drug Form 483s citing Part 21
- [FDA Quality Agreements: What the Guidance Requires and Where Contracts Fail](https://www.atlas-compliance.ai/blog/fda-quality-agreements): A quality agreement is the written document in which a drug owner and a contract facility assign each CGMP activity. This guide covers what FDA's November 2016 guidance says, whether a quality agreement is required, a section-by-section che
- [The FDA quality metrics program in 2026: practice areas, QMM, and what Form 483s measure](https://www.atlas-compliance.ai/blog/fda-quality-metrics-program): What the FDA quality metrics program is, why reporting is still not required, the four practice areas FDA proposed in 2022 with their example metrics, how the program differs from CDER's voluntary Quality Management Maturity assessments, an
- [510(k) submission guide: what a 510(k) is, how FDA reviews it, and what inspectors check after clearance](https://www.atlas-compliance.ai/blog/510k-submission-guide): A 510(k) is the premarket notification a device maker files with FDA to show a new device is substantially equivalent to a legally marketed predicate. This guide covers who must submit, the exemptions, Traditional, Special and Abbreviated 5
- [Continued Process Verification (CPV): FDA Requirements, Metrics and a Review Checklist](https://www.atlas-compliance.ai/blog/continued-process-verification): Continued process verification is the ongoing monitoring that shows a validated commercial process stays in a state of control. This guide covers the FDA requirements behind CPV, how often drug 483s cite process monitoring, the metrics wort
- [Combination products: the FDA definition, PMOA and the Part 4 cGMP rules](https://www.atlas-compliance.ai/blog/fda-combination-products): A combination product combines a drug, device or biological product into one product, one package or a cross-labeled pair. This guide covers the FDA definition in 21 CFR 3.2(e), the three types with examples, how primary mode of action deci
- [FDA foreign inspections in 2026: unannounced visits, the refusal rule, and the Form 483s by country](https://www.atlas-compliance.ai/blog/fda-foreign-inspections): FDA inspects about 3,000 foreign facilities a year and now arrives at most Indian sites without notice. This guide covers the legal basis, what refusing or limiting an inspection triggers, 704(a)(4) records requests and Import Alert 66-79, 
- [FDA inspection types: surveillance, for-cause, pre-approval and follow-up](https://www.atlas-compliance.ai/blog/fda-inspection-types): FDA runs four types of inspections: surveillance, for-cause, application-based (pre-approval and pre-license) and follow-up. This guide explains what triggers each, how FDA picks sites for routine inspections, what a records request in lieu
- [FDA IOM: what the Investigations Operations Manual tells investigators, and what it tells you](https://www.atlas-compliance.ai/blog/fda-investigations-operations-manual): The Investigations Operations Manual (IOM) is the primary operational reference for FDA investigators. This guide covers the 2026 edition, its ten chapters, the Chapter 5 sections an inspected firm should read (credentials, Form FDA 482, re
- [FDA Untitled Letters: What They Are, Who Sends Them and What Follows](https://www.atlas-compliance.ai/blog/fda-untitled-letter): An FDA untitled letter is an advisory letter for violations that do not meet the threshold for a warning letter. This guide covers how the Regulatory Procedures Manual separates the two, which FDA offices send untitled letters, the 15 worki
- [Medical device design controls under the QMSR: what FDA cites in 2026](https://www.atlas-compliance.ai/blog/medical-device-design-controls): Medical device design controls are the documented steps that turn user needs into a verified, validated device design. Since February 2, 2026, FDA enforces them through the QMSR and ISO 13485:2016 clause 7.3 instead of 21 CFR 820.30. This g
- [Regeneron FDA Form 483 in 2026: East Greenbush, Rensselaer and the filler CRLs](https://www.atlas-compliance.ai/blog/regeneron-fda-483-2026): What is public about the January 2026 Form 483 at Regeneron's East Greenbush, New York facility, the inspection record of five Regeneron facilities in Atlas (39 inspections, 13 ending in a Form 483), the citations FDA has written at Renssel
- [Hetero Labs FDA inspection history: every unit, every 483, and where things stand](https://www.atlas-compliance.ai/blog/hetero-labs-fda-inspection-history): A unit-by-unit record of FDA inspections at Hetero Labs and Hetero Drugs facilities in India and the US: 54 inspections, 34 Form 483 outcomes, the citations FDA repeats, the 2017 Unit V warning letter and its 2022 closeout, the clean 2025 i
- [ICH Q9 quality risk management: what Q9(R1) requires in practice](https://www.atlas-compliance.ai/blog/ich-q9-quality-risk-management): ICH Q9 sets the principles for quality risk management (QRM) across the drug product lifecycle. This guide explains what the 2023 Q9(R1) revision changed, walks through the QRM process and formality tiers, shows how to link QRM to CAPA, cha
- [Computerized system validation: OQ audit trail tests for life sciences](https://www.atlas-compliance.ai/blog/computerized-system-validation-audit-trail-tests): Computerized system validation is the documented, risk-based evidence that a regulated computer system works as intended and keeps its data trustworthy. This guide covers the expectations in FDA's CSA guidance, Part 11, EMA and ICH E6(R3), 
- [FDA 483 vs warning letter: who gets 15 working days to respond?](https://www.atlas-compliance.ai/blog/fda-483-vs-warning-letter-response): A Form FDA 483 is the investigator's list of observations at the close of an inspection. A warning letter is a formal advisory FDA issues later, after review, when it judges violations significant. This guide explains the 15 business day re
- [Chlorthalidone recall 2026: two dissolution failures, the lots, and the manufacturer's FDA record](https://www.atlas-compliance.ai/blog/chlorthalidone-recall-2026): Chlorthalidone 25 mg tablets made by Inventia Healthcare in India and distributed by Rising Pharma were recalled twice in 2026, in June and September, for failed dissolution specifications. This piece covers the lots, what a dissolution fai
- [CSA vs CSV for life sciences: five stages inspectors can trace](https://www.atlas-compliance.ai/blog/csa-vs-csv-life-sciences): Computer System Validation proves software works through specifications and scripted tests; Computer Software Assurance sizes the effort to risk. This guide covers FDA's four-step CSA approach, a five-stage governance model, how to apply it
- [Mock FDA inspections: four formats for quality teams facing the 2026 QMSR](https://www.atlas-compliance.ai/blog/mock-fda-inspections-2026): A mock FDA inspection tests your records, procedures, interviews and facility the way an investigator would, without regulatory authority. This guide covers choosing the right format, a ten-step sequence, the findings investigators cite mos
- [Olympus FDA warning letter 2026: the six facilities, and the 483s behind it](https://www.atlas-compliance.ai/blog/olympus-fda-warning-letter-2026): Olympus received an FDA warning letter dated October 7, 2026 covering six facilities. This piece lays out the late-2025 Form 483s at each site, the regulations cited, the investigators involved, Hachioji's earlier warning-letter history, an
- [Fresenius Kabi FDA warning letter 2026: Melrose Park, the Ogden letter, and the 483s behind them](https://www.atlas-compliance.ai/blog/fresenius-fda-warning-letters-2026): Two Fresenius facilities received FDA warning letters within four weeks of each other in 2026. This piece explains what the Ogden, Utah and Melrose Park, Illinois letters cite, the Form 483s and inspections that preceded them, the group's w
- [What Is an FDA Form 483? Observations, Responses, and What Happens Next](https://www.atlas-compliance.ai/blog/what-is-an-fda-form-483): An FDA Form 483 is the list of inspectional observations an FDA investigator hands to management at the close of an inspection. This guide covers what a 483 contains, how many FDA issues each year, what a typical one looks like, how to resp
- [FDA Complete Response Letters: What 438 Published CRLs Say About Facility Readiness](https://www.atlas-compliance.ai/blog/fda-complete-response-letters-facility-readiness-form-483): Every published FDA Complete Response Letter, classified against its own wording. Facility readiness appears in roughly half, the four sentences the agency reuses, the two ways teams misread the record, and six checks to run before filing.
- [Claude or OpenAI? Why the model is the easiest part of AI adoption in pharma quality.](https://www.atlas-compliance.ai/blog/ai-adoption-model-selection-pharma-quality): About 25% of pharma and medical device organizations are piloting AI for regulatory and compliance review — but the model isn't the constraint. Legacy QMS data, process variation, and budget framing are where adoption stalls.
- [Rolling out an AI module in your QMS: what to look out for (the model is one of them)](https://www.atlas-compliance.ai/blog/ai-module-qms-rollout-guide): Your QMS vendor just shipped an AI module, and the demo focused on the model. But infrastructure, change management, and QMS-ERP integration — the technologistics layer above the model — are where most AI rollouts in regulated quality funct
- [Your CEO just mandated AI adoption. Here's the five-line memo your chief of QA-RA actually needs.](https://www.atlas-compliance.ai/blog/ceo-ai-mandate-quality-memo): The CEO came back from a conference and wants an AI strategy for quality. The honest, board-ready version is 5 lines: one capability shipped, one pilot named, one thing you're explicitly not doing, your data integrity approach, and what you
- [How an FDA Guidance Monitoring Database Reduces Inspection Risk?](https://www.atlas-compliance.ai/blog/how-an-fda-guidance-monitoring-database-reduces-inspection-risk): Most FDA inspection risks come from missed guidance updates, fragmented monitoring, and lack of evidence that regulatory changes were tracked. A dedicated guidance monitoring database like Hedwig centralizes global guidance, tracks updates 
- [What prevents teams from shifting from reactive to proactive compliance?](https://www.atlas-compliance.ai/blog/what-prevents-teams-from-shifting-from-reactive-to-proactive-compliance): Every compliance team wants to be proactive. They want to spot changes early, assess impact quickly, and act before an investigator raises an issue.
- [Are pharma companies ready for FDA audits of eLogs and digital batch records?](https://www.atlas-compliance.ai/blog/are-pharma-companies-ready-for-fda-elog-and-ebatch-audits): The shift from paper to electronic logs (eLogs) and electronic batch records (eBMRs) is accelerating across pharma manufacturing.
- [Can AI-generated procedures or RCA reports be considered FDA-compliant?](https://www.atlas-compliance.ai/blog/can-ai-generated-procedures-or-rca-reports-be-considered-fda-compliant): AI can help generate procedures and Root Cause Analysis (RCA) reports, but AI-generated documents are not automatically FDA-compliant. Compliance depends on system design, data provenance, human oversight, and validation.
- [Can LLM-based quality systems pass an FDA Part 11 audit?](https://www.atlas-compliance.ai/blog/can-llm-based-quality-systems-pass-an-fda-part-11-audit): Yes, LLM-based quality systems can pass an FDA Part 11 audit, but only with validation of intended use, controlled inputs and outputs, ALCOA+ data integrity, audit trails, rigorous change control, and human oversight. This guide walks throu
- [How will AI-driven inspection models change FDA audits in the next 5 years?](https://www.atlas-compliance.ai/blog/how-will-ai-driven-inspection-models-change-fda-audits-in-the-next-5-years): AI-driven inspection models will enable FDA audits to be faster, more data-driven, and more focused on high-risk signals.
- [Top Repeat FDA Violations: What Keeps Getting Companies in Trouble?](https://www.atlas-compliance.ai/blog/which-issues-get-companies-in-trouble-with-the-fda-most-often): Repeat FDA violations keep showing up across drug, biologic, and device manufacturers because problems are systemic, including weak quality systems, sloppy data integrity, poor documentation, and inadequate CAPA and training.
- [How has the FDA's approach to overseas inspections changed in 2024-2025?](https://www.atlas-compliance.ai/blog/fdas-new-overseas-inspection-approach-2024-2025): Between 2024 and 2025, the FDA shifted from pandemic-era stop-start inspection tactics to a sustained, more aggressive, data-driven, and technology-enabled oversight posture for foreign facilities.
- [What documentation failures are being highlighted in 2024, 2025 FDA inspections?](https://www.atlas-compliance.ai/blog/what-documentation-failures-did-the-fda-flag-in-2024-2025): Across 2024 and 2025 FDA inspections, the biggest documentation failures involve data integrity and poor recordkeeping: missing batch records, altered lab data, weak CAPA investigations, and incomplete deviation files. This post covers what
- [What is the FDA's new AI tool "Elsa" and how does it impact inspections?](https://www.atlas-compliance.ai/blog/what-is-fdas-ai-tool-elsa-and-its-impact-on-inspections): The FDA's new internal generative-AI assistant ELSA (Enterprise Language Support Assistant) is an agency-wide tool launched in June 2025 to help reviewers, investigators, and scientists read, summarize, and prioritize large volumes of regul
- [Why do so many companies receive citations for weak CAPA and investigation systems?](https://www.atlas-compliance.ai/blog/why-do-companies-still-fail-capa-and-investigation-requirements): Weak CAPA and investigation systems drive a high share of Form 483s and warning letters. This guide breaks down why investigations stop at "human error," how regulators read CAPA records, and the specific procedure, RCA, and governance fixe
- [Why is the FDA increasing unannounced inspections at foreign facilities?](https://www.atlas-compliance.ai/blog/why-is-the-fda-increasing-unannounced-foreign-inspections): In May 2025 the FDA expanded unannounced inspections at foreign manufacturing sites. This piece breaks down the six reasons behind the shift, what the agency actually said, the investigator workforce reality, and how pharma and medical devi
- [FDA Releases 76 New PSGs: What Quality and Compliance Teams Must Know](https://www.atlas-compliance.ai/blog/fda-releases-76-new-psgs-key-updates-for-complianceteams): The FDA released 76 new Product-Specific Guidances, including 64 for drugs without approved generics and 29 for complex products. This guide breaks down how quality, compliance, and regulatory teams should use PSGs to reshape development pl
- [What Are the FDA's Latest Expectations for SaMD Submissions?](https://www.atlas-compliance.ai/blog/what-are-the-fdas-latest-expectations-for-samd-submissions): The FDA's expectations for SaMD (Software as a Medical Device) submissions have shifted to a total product life cycle (TPLC) model emphasizing risk, data governance, human factors, and post-market monitoring. This guide breaks down what rev
- [CAPA Effectiveness Checks and Metrics: How to Prove a Fix Worked](https://www.atlas-compliance.ai/blog/what-are-the-key-metrics-for-capa-effectiveness): A CAPA effectiveness check proves that the problem behind a CAPA did not come back. This guide separates effectiveness from verification, sets out the four fields every check needs, compares the methods that produce real evidence, explains 
- [What Does the FDA Look for During Inspections of Foreign Contract Manufacturers?](https://www.atlas-compliance.ai/blog/what-does-the-fda-check-in-foreign-contract-manufacturing-sites): The FDA is increasing inspections of foreign contract manufacturers, often without notice. Investigators focus on quality systems, data integrity, sterility controls, process validation, labs, supplier quality, and complaint handling. This 
- [What Should Global Manufacturers Know About the New Import Framework?](https://www.atlas-compliance.ai/blog/what-should-manufacturers-know-about-import-alerts): FDA Import Alerts can trigger detention without physical examination and freeze revenue at the border. This guide explains how the framework works, which root causes drive alerts, and the upstream quality and documentation practices manufac
- [What Technologies Are Enabling Continuous Supplier Monitoring?](https://www.atlas-compliance.ai/blog/what-technologies-are-enabling-continuous-supplier-monitoring): Continuous supplier monitoring has replaced periodic audits for pharma and medical device manufacturers. This guide walks through every technology behind the shift, from IoT sensors and AI risk scoring to digital twins and control towers, w
- [How ALCOA+ Is Evolving With AI and Digital Systems in 2025?](https://www.atlas-compliance.ai/blog/how-is-alcoa-evolving-with-ai-and-digital-systems-in-2025): In 2025, the principles of ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available, Traceable) are...
- [What are the top deviation trends in FDA 483s and Warning Letters?](https://www.atlas-compliance.ai/blog/what-are-the-key-deviation-trends-in-fda-483s-and-warning-letters): FDA Form 483 observations and Warning Letters point to the same recurring root causes: data integrity lapses, weak quality systems (CAPA and investigations), incomplete batch records, training gaps, and equipment controls. This post breaks 
- [What's New in the FDA's 2025 Draft Guidance on AI/ML in Drug and Device Development?](https://www.atlas-compliance.ai/blog/whats-new-in-the-fdas-2025-ai-ml-draft-guidance): The FDA's 2025 AI/ML draft guidances shift from exploratory policy to operational expectations. Key changes include a risk-based credibility framework, lifecycle recommendations for AI-enabled device software, stronger data quality and bias
- [eCTD 4.0 Timeline and Regulatory Submission Automation: What Changes in 2026](https://www.atlas-compliance.ai/blog/smart-automation-for-regulatory-submissions-in-pharma): eCTD v4.0 is the ICH M8 version of the electronic Common Technical Document. This guide gives the eCTD 4.0 timeline for FDA, EMA, PMDA and Health Canada as of October 2026, explains what changes from v3.2.2, separates the submission tasks s
- [What's New in eCTD Module 1 Regional Specifications for the US and EU in 2025?](https://www.atlas-compliance.ai/blog/whats-new-in-ectd-module-1-for-us-and-eu-in-2025): Module 1 for the eCTD has been updated in both the US and EU during 2024 and 2025 with clearer validation criteria, controlled vocabularies, and machine-readable metadata to support the gradual global shift to eCTD v4.0.
- [What Mistakes Are Companies Making During eCTD v4.0 Implementation?](https://www.atlas-compliance.ai/blog/common-mistakes-in-ectd-v4-0-implementation): eCTD v4.0 is a structural and data-driven upgrade to the electronic Common Technical Document, changing how dossiers are built, indexed, and delivered.
- [Can Regulatory Intelligence Reduce Repeated 483 Observations?](https://www.atlas-compliance.ai/blog/can-regulatory-intelligence-reduce-repeated-483-observations): Regulatory intelligence, when integrated with a modern quality ecosystem (digital QMS, MES, MCP, CAPA analytics, and AI), can materially reduce repeat FDA Form 483 observations by turning reactive fixes into systemic prevention.
- [What Should QA Teams Prepare Before an Unannounced Inspection Occurs?](https://www.atlas-compliance.ai/blog/what-should-qa-teams-prepare-before-an-unannounced-inspection-occurs): Prepare as if inspections are always possible. QA teams must keep documentation current, systems validated, staff trained, and evidence traceable.
- [How does MCP improve data integrity and traceability for QA teams in pharma and medical devices?](https://www.atlas-compliance.ai/blog/how-mcp-enhances-data-integrity-and-traceability-in-life-sciences-qa): Model Context Protocol turns ELNs, LIMS, MES, and QMS into discoverable, auditable interfaces for AI agents. For QA teams, it means fewer transcription errors, tamper-resistant audit trails, stronger ALCOA+ provenance, and faster root-cause
- [How MCP Streamlines Quality Audits and Documentation in Pharma and Medical Devices?](https://www.atlas-compliance.ai/blog/how-mcp-streamlines-quality-audits-and-documentation-in-life-sciences): Pharma and medical device QA teams still fight version mismatches, manual evidence collation, and slow inspection responses. Model Context Protocol connects AI agents to MES, LIMS, QMS, and document repositories in a governed way, so audit-
- [What are the security challenges of adopting MCP in pharma and medical devices?](https://www.atlas-compliance.ai/blog/what-are-the-security-challenges-of-adopting-mcp-in-life-sciences): Model Context Protocol gives AI agents a standardized way to reach ELNs, LIMS, QMS, and regulatory systems. It also introduces prompt injection, IP exfiltration, over-privileged delegation, and GxP audit-trail gaps that pharma and medical d
- [What future trends will shape MCP use cases in the pharmaceutical industry?](https://www.atlas-compliance.ai/blog/what-future-trends-will-shape-mcp-use-cases-in-the-pharmaceutical-industry): The Model Context Protocol (MCP) is becoming the standard layer that lets LLMs and agentic AI interact safely with enterprise systems. This post covers the trends shaping MCP adoption in pharma, from governance and federated identity to reg
- [What are key MCP use cases in pharma R&D?](https://www.atlas-compliance.ai/blog/what-are-key-mcp-use-cases-in-pharma-rd): The Model Context Protocol (MCP) is a new standard that allows AI models to connect easily with data, systems, and tools.
- [Is MCP Ready for Generative AI in Drug Design?](https://www.atlas-compliance.ai/blog/is-mcp-ready-for-next-generation-generative-ai-in-drug-design): The Model Context Protocol (MCP) is an emerging open standard that lets large generative models connect securely with external data sources, tools, and workflows. In drug design, it helps AI access lab data and structure libraries in a stan
- [Can MCP cut costs while ensuring GMP compliance?](https://www.atlas-compliance.ai/blog/can-mcp-cut-costs-while-ensuring-gmp-compliance): MCP (Model Context Protocol) is a rapidly adopted open standard that lets AI agents securely and consistently access company data, tools, and workflows.
- [Can MCP Create a Standardized Data Layer that Enhances Cross-Border Collaboration in Multinational Trials?](https://www.atlas-compliance.ai/blog/how-mcp-enables-cross-border-data-collaboration-in-trials): Yes. MCP (Model Context Protocol) can build a standardized data layer that bridges silos across sponsors, CROs, and regulators in multinational trials.
- [How can MCP strengthen pharmacovigilance by ensuring faster detection of adverse events with fewer manual errors?](https://www.atlas-compliance.ai/blog/how-mcp-accelerates-pharmacovigilance-with-fewer-errors): Model Context Protocol (MCP) is improving pharmacovigilance by enabling near-real-time data sharing, faster signal detection, and fewer manual errors in adverse event reporting. This post explains how MCP connects safety databases, regulato
- [What role does MCP play in integrating AI with digital twins for predictive maintenance and quality control?](https://www.atlas-compliance.ai/blog/what-role-does-mcp-play-in-integrating-ai-with-digital-twins-for-predictive-maintenance-and-quality-control): MCP (Model Context Protocol) is emerging as the backbone of AI and digital twin integration in pharma and medical devices. It links near-real-time equipment and quality data to AI models for predictive maintenance, process optimization, and
- [How does MCP improve efficiency in scaling AI models from research labs to commercial manufacturing?](https://www.atlas-compliance.ai/blog/mcp-for-scaling-ai-models-from-research-to-manufacturing): Artificial intelligence has already improved how research is carried out in pharma and medical devices, but the real challenge comes when we try to scale these models beyond the lab and into commercial manufacturing. MCP offers a standardiz
- [Can MCP Deliver Real-Time Decisions in R&D While Ensuring Compliance?](https://www.atlas-compliance.ai/blog/can-mcp-deliver-real-time-decisions-in-rd-while-ensuring-compliance): MCP can support near-real-time decision-making across global R&D hubs without compromising compliance, but only with secure architecture, strong governance, and risk-based regulatory strategy. This post covers the blueprint, risks, and oper
- [How Does MCP Reduce Human Error in Clinical Data and Regulatory Reporting?](https://www.atlas-compliance.ai/blog/how-does-mcp-reduce-human-error-in-clinical-data-and-regulatory-reporting): MCP cuts human error in clinical data management and regulatory reporting. It standardizes data interactions, automates processing, enables near-real-time validation, and creates detailed audit trails, so teams ship faster with fewer mistak
- [MCP for Regulators: Ensuring Reproducible AI Research](https://www.atlas-compliance.ai/blog/mcp-for-regulators-ensuring-reproducible-ai-research): MCP gives AI systems a standard way to access regulated data and tools. For pharma research, that means AI outputs become reproducible, traceable, and easier for regulators to verify, while cutting integration effort and human error.
- [How MCP Can Break Down Data Silos and Improve Collaboration in Pharma and Medical Device R&D](https://www.atlas-compliance.ai/blog/how-mcp-can-break-down-data-silos-and-transform-collaboration-in-life-sciences-rd): Data silos slow pharma and medical device R&D, causing inefficiencies and errors. MCP enables AI systems to access and integrate data across departments securely, streamlining workflows and accelerating decision-making.
- [Model Context Protocol (MCP): A Guide for Pharma and Medical Device Leaders](https://www.atlas-compliance.ai/blog/ais-model-context-protocol-mcp-what-pharma-life-sciences-leaders-need-to-know-in-2025): MCP is an open standard that lets AI systems connect securely to data, apps, and services. For pharma and medical device leaders, it can speed trial design, improve regulatory visibility, and break down data silos, but it also creates new s
- [What Role Does AI Play in Detecting Compliance Gaps Before FDA Inspections?](https://www.atlas-compliance.ai/blog/what-role-does-ai-play-in-detecting-compliance-gaps-before-fda-inspections): AI is a practical capability for quality teams preparing for FDA inspections. Used well, it converts manual document review into reproducible queries, scores CAPA risk, and surfaces recurring observations across sites and suppliers.
- [How are continuous monitoring & GenAI validation transforming pharma and medical devices quality assurance in 2025?](https://www.atlas-compliance.ai/blog/how-are-continuous-monitoring-genai-validation-transforming-life-sciences-quality-assurance-in-2025): In 2025, pharma and medical device quality assurance is going through a major shift. Continuous monitoring allows near-real-time tracking of manufacturing processes, while generative AI validation brings smarter risk detection and faster co
- [How Does the FDA's GLP-1 Import Alert Impact Global Obesity Drug Quality Control?](https://www.atlas-compliance.ai/blog/fdas-glp-1-import-alert-impact-global-obesity-drug-quality-control): The FDA issued an import alert targeting GLP-1 ingredients to stop counterfeit and substandard raw materials. This post covers what the alert does, how it affects global suppliers, and what quality teams need to change to keep market access
- [How Do Atlas Real-Time Alerts Redefine Supplier Compliance Management?](https://www.atlas-compliance.ai/blog/how-atlas-real-time-alerts-redefine-supplier-compliance-management): Supplier compliance has become a strategic priority for pharma and medical device companies. Atlas real-time alerts notify quality teams via email and WhatsApp the moment a supplier or external manufacturer gets inspected, receives a 483, o
- [Using LLMs to Detect Regulatory Contradictions in SOPs](https://www.atlas-compliance.ai/blog/how-can-gpt-4-detect-contradictions-in-sops-and-improve-compliance): Regulators update rules constantly and SOPs drift. This post covers how LLMs like GPT-4 detect contradictions between internal SOPs and regulatory requirements, what the benefits look like, and the risks teams need to manage.
- [Why Are Real-Time Alerts Changing Supplier Compliance for Good?](https://www.atlas-compliance.ai/blog/why-are-real-time-alerts-changing-supplier-compliance-for-good): Supplier compliance is about speed, signals, and clear actions. This post covers why traditional methods fail, what real-time alerts actually do, and how to deploy monitoring, bulk upload, site-level tracking, and analysis features that red
- [Atlas for Proactive CAPA Strategy in Multinational Pharma](https://www.atlas-compliance.ai/blog/why-atlas-is-becoming-essential-for-proactive-capa-strategy-in-multinational-pharma-firms): CAPA is the backbone of pharma quality, and inspection findings keep citing weak investigations. This post shows how Atlas feeds inspection intelligence, investigator patterns, and enforcement signals into every stage of the CAPA lifecycle.
- [How the EU AI Act Will Reshape Global Business Compliance Strategies](https://www.atlas-compliance.ai/blog/how-the-eu-ai-act-will-reshape-global-business-compliance-strategies): The EU AI Act takes full effect in August 2026. This post covers the risk classification, the compliance building blocks (governance, documentation, oversight, conformity assessments), and a multi-year roadmap for global product and complia
- [What Solutions Can Ease Supplier Overload from Fragmented Compliance Data Requests](https://www.atlas-compliance.ai/blog/what-solutions-reduce-supplier-compliance-data-burden): Suppliers receive dozens of duplicate compliance data requests every quarter across different formats. This post covers why fragmentation is expensive, what buyers and suppliers can do to simplify it, and how supply chain monitoring tools c
- [How Can Businesses Govern AI Responsibly Under GDPR, Monitoring, and Hallucination Risks?](https://www.atlas-compliance.ai/blog/manage-ai-risks-like-gdpr-monitoring-and-hallucinations): AI is no longer experimental, and GDPR enforcement is accelerating. This post covers the governance basics that hold up in audit: lawful basis, DPIAs, monitoring limits, hallucination controls, and a practical checklist for the next 30 days
- [Why NIS2 Is Still Hard for Companies, Even With Automation Tools](https://www.atlas-compliance.ai/blog/why-nis2-is-still-hard-for-companies-even-with-automation-tools): NIS2 raised the cybersecurity bar across the EU, but only 14% of organizations report being fully ready. This post covers the scope, why automation tools can't close the gap on their own, and a practical roadmap for governance, supplier ove
- [Do Warning Letters Impact Pharma Stock Investments?](https://www.atlas-compliance.ai/blog/do-warning-letters-impactpharma-stock-investments): FDA warning letters create real risks for pharma investors: production disruption, import alerts, recalls, legal costs, and delayed approvals. This post breaks down how regulators escalate, what the market reacts to, and the checklist to ru
- [How Does the FDA's Drug Supply Chain Security Act Affect Your Business?](https://www.atlas-compliance.ai/blog/how-does-the-fdas-drug-supply-chain-security-act-affect-yourbusiness): By 2025, manufacturers, distributors, and most pharmacies must comply with DSCSA serialization, verification, and tracing requirements. Here's a plain-language breakdown of the rules, the enforcement timeline, and how quality teams track co
- [Why QA Teams Are Choosing Atlas AI Copilot in 2025](https://www.atlas-compliance.ai/blog/why-are-qa-teams-choosing-atlas-ai-copilot-in-2025): FDA inspections surged in FY2025 and unannounced foreign inspections went global. QA teams are using the Atlas AI copilot to see what each investigator focuses on, what they commonly cite, and how to prepare before they arrive on site.
- [What Is a Nonconformance? Types, the NCR, and How FDA Cites It](https://www.atlas-compliance.ai/blog/non-conformance-types-prevention): A nonconformance (also written non-conformance or nonconformity) is any failure to meet a specified requirement. This guide covers the ISO 9000 definition, the critical, major and minor types with GMP examples, the fields of a nonconformanc
- [OOS Meaning in Pharma: Out of Specification Results, OOS vs OOT, and the FDA Investigation](https://www.atlas-compliance.ai/blog/understanding-oos-key-meanings-uses): OOS stands for Out of Specification, a test result that falls outside the approved acceptance criteria. This guide explains the OOS meaning in pharma, how it differs from OOT, the phase I laboratory and phase II full-scale investigation in 
- [Quality Control Methods in Pharma: Definitions and Practical Use](https://www.atlas-compliance.ai/blog/understanding-quality-control-methods): Discover what quality control is and the essential methods used. Learn about inspection, SPC, and tools like Pareto charts.
- [What Is a Corrective Action Request (CAR)? Process, Form and ISO Rules](https://www.atlas-compliance.ai/blog/corrective-action-request-key-concepts-procedures): A corrective action request (CAR) is the internal document that assigns a nonconformity to an owner, who must find the root cause, fix it and prove the fix works. This guide covers when a CAR is raised, the CAR workflow step by step, what a
- [Preparing for FDA QSIT Inspections: What to Expect](https://www.atlas-compliance.ai/blog/expect-fda-qsit-inspection): QSIT inspections drill into four quality subsystems with a top-down logic: management controls, CAPA, design controls, and production and process controls. This guide shows quality teams how to prepare before the FDA walks in.
- [Where to Find FDA 483 Reports (and How to Read One)](https://www.atlas-compliance.ai/blog/fda-483-reports-database): There are three routes to an FDA Form 483: FDA's FOIA electronic reading room, a FOIA request, or a searchable database. This guide compares them on coverage, wait time and search, then explains how to read a 483 once you have it, with thre
- [What Is CGMP? FDA Current Good Manufacturing Practice Explained](https://www.atlas-compliance.ai/blog/fda-gmp-current-good-manufacturing-practices-overview): CGMP stands for Current Good Manufacturing Practice, the FDA regulations that set minimum requirements for the methods, facilities and controls used to make regulated products. This guide covers why the "C" matters, GMP vs CGMP, which CFR p
- [NAI, VAI, OAI: What Each FDA Inspection Classification Means](https://www.atlas-compliance.ai/blog/fda-inspection-vai-nai-oai-explained): Every FDA inspection ends with one of three classifications: NAI (no action indicated), VAI (voluntary action indicated) or OAI (official action indicated). This guide explains what each means, how FDA decides after a Form 483 and the compa
- [FDA Warning Letter Database: How to Search It and Trace a Letter to Its 483](https://www.atlas-compliance.ai/blog/fda-warning-letter-database-guide): FDA posts its warning letters in a searchable table on fda.gov. This guide shows how to search it by company, issuing office, subject and date, how to read closeout and response letters, what a warning letter contains, and how to connect an
- [Supplier Qualification: How to Ensure Quality in Pharma](https://www.atlas-compliance.ai/blog/high-quality-supplier-qualification): Unqualified suppliers cause violations, poor materials, and costly recalls. This guide walks quality teams through a structured supplier qualification process, the regulations that apply, and how to monitor performance over time.
- [Preparing for FDA Pre-Approval Inspections: A Practical Guide](https://www.atlas-compliance.ai/blog/prepare-fda-pre-approval-inspections): FDA Pre-Approval Inspections decide whether your product ships on time or stalls. This guide covers triggers, objectives, and a step-by-step readiness plan so quality teams can walk investigators through the facility with confidence.
- [Pharma Change Control: 21 CFR 211.100 and 820.70](https://www.atlas-compliance.ai/blog/understanding-change-control-project-management): Change control is how regulated teams manage project modifications without breaking compliance. This guide covers the four types of change control, a six-step process, and a pharma manufacturing example showing it in action.
- [What Is a Consent Decree? FDA Consent Decrees Explained, With Examples](https://www.atlas-compliance.ai/blog/understanding-consent-decree-fda-implications): An FDA consent decree is a court order, usually a permanent injunction, that a company agrees to after the Department of Justice sues on FDA's behalf. This guide explains how a firm reaches one, what the decree requires, how long it lasts a
- [Environmental Regulatory Compliance for Pharmaceuticals and FDA](https://www.atlas-compliance.ai/blog/environmental-regulatory-compliance-pharmaceuticals-fda): In an industry known for medical innovation, the pharmaceutical sector also faces growing scrutiny over its environmental impact and compliance...
- [FDA EIR (Establishment Inspection Report): What It Contains and How to Get One](https://www.atlas-compliance.ai/blog/fda-eir-insights-readiness): The EIR, or Establishment Inspection Report, is the FDA investigator's full written account of an inspection. This guide compares it with the Form 483 and the classification letter, walks through each section of the report, explains when FD
- [KVK-Tech FDA warning letters: the 2020 letters, the 483s behind them and what followed](https://www.atlas-compliance.ai/blog/fda-kvk-tech-warning-letters-explained): FDA sent KVK-Tech two warning letters in 2020: February 11 for test methods, investigations and lab data controls at 110 Terry Drive, and October 8 for cleaning validation and batch records at 100 Campus Drive. This piece sets the letters s
- [FDA Warning Letters: What They Mean, Common Violations and How to Respond](https://www.atlas-compliance.ai/blog/fda-violations-warning-letters-explained): An FDA warning letter is the agency's formal notice that it found significant violations and expects them corrected. This guide covers where the letter sits on FDA's escalation ladder, what it contains, the regulations most often cited on t
- [SCAR Meaning: The Supplier Corrective Action Request Process](https://www.atlas-compliance.ai/blog/scar-process-guide-supplier-corrective-action): A SCAR (Supplier Corrective Action Request) is the formal request a manufacturer sends a supplier to find and fix the root cause of a nonconformance. This guide covers the seven steps of the SCAR process, how a SCAR differs from a CAR and a
- [What is an EDMS? Electronic document management system meaning, types and GxP requirements](https://www.atlas-compliance.ai/blog/understand-edms-document-management): An EDMS (electronic document management system) is the software that controls a regulated company's procedures, specifications and records from draft to retirement. This guide covers the meaning and full form, the five types, the 21 CFR Par
- [What metrics should QA teams track for compliance success?](https://www.atlas-compliance.ai/blog/qa-metrics-for-compliance-success): Quality Assurance (QA) teams are the silent guardians of compliance in regulated industries. Yet, many organizations overlook the key metrics that reflect...
- [FDA Form 483 Response Strategies: A 10-Step Template](https://www.atlas-compliance.ai/blog/effective-fda-form-483-response-strategies): Getting hit with an FDA Form 483 should be a wake-up call. As these observations are often made public, your company is under a tangible risk of losing...
- [GxP Compliance: A Practical Guide for Pharma and Medical Device Teams](https://www.atlas-compliance.ai/blog/gxp-compliance-essential-guide): GxP covers the full spectrum of Good Practices, from manufacturing to pharmacovigilance. This guide explains the key components, compliance challenges, and how modern tools help pharma and medical device quality teams stay audit-ready.
- [Regulatory Compliance in the Pharmaceutical Industry](https://www.atlas-compliance.ai/blog/pharmaceutical-compliance-regulatory-understanding): Pharmaceutical regulatory compliance spans the full drug lifecycle, from IND to post-market surveillance. This guide covers the major regulatory bodies, core standards, and practical strategies quality teams use to stay audit-ready across F
- [Complete Warehouse FDA Inspection Readiness Checklist](https://www.atlas-compliance.ai/blog/warehouse-fda-inspection-readiness-checklist): The FDA runs about 12,000 domestic and 3,000 foreign inspections a year. This warehouse readiness checklist walks through structural integrity, hygiene, hazard management, and inspection-day protocols so your team stays calm, compliant, and
- [100 Things FDA Investigators Look for During Inspections](https://www.atlas-compliance.ai/blog/100-things-fda-inspectors-look-for-during-inspections): FDA inspections evaluate your quality systems, documentation, and risk posture. This 100-point checklist covers what investigators actually review on site, from ALCOA+ data integrity to training records, equipment qualification, and clinica
- [CAPA in Pharma and Medical Devices: Corrective and Preventive Action Guide (2026)](https://www.atlas-compliance.ai/blog/2025-guide-to-corrective-and-preventive-action): CAPA stands for Corrective and Preventive Action: the quality system process that finds the cause of a problem, removes it, and proves it will not recur. This guide covers the definition, corrective vs preventive action, the process step by
- [What Are the Key Biological Approvals and Regulatory Developments of 2025?](https://www.atlas-compliance.ai/blog/the-key-biological-approvals-and-regulatory-developments-of-2025): In 2025, CBER approved new biological products and devices while issuing guidance on gene therapy, laboratory developed tests, and IVDR compliance. Here's what pharma and medical device quality teams need to know about the year's key approv
- [What Are the Latest FDA Regulations Impacting Medical Device Manufacturers?](https://www.atlas-compliance.ai/blog/latest-fda-regulations-impacting-medical-device-manufacturers): The FDA has rolled out major changes for medical device manufacturers, from QMSR alignment with ISO 13485 to stronger cybersecurity requirements, a risk-based SaMD framework, expanded post-market surveillance, and a refined 510(k) pathway. 
- [Does Atlas provide real-time inspection and regulatory event notifications?](https://www.atlas-compliance.ai/blog/does-atlas-offer-real-time-inspection-alerts): Atlas delivers proactive alerts on FDA inspections, 483s, warning letters, recalls, and enforcement events. New data typically arrives within a business week, through proprietary market intelligence, before it's on the FDA website.
- [Can I Search for Specific FDA Investigators and Their Inspection History?](https://www.atlas-compliance.ai/blog/fda-investigators-and-their-inspection-history): When a quality team learns who's assigned to their site, the first thing they do is search the investigator by name. Atlas has 6,000+ FDA investigator reports covering inspection history, focus areas by CFR code, and how citation patterns h
- [How Atlas Helps Pharma and Medical Device Companies With FDA Inspections](https://www.atlas-compliance.ai/blog/how-atlas-helps-life-sciences-companies-with-fda-inspections): FDA inspections are high-stakes for pharma and medical device companies, yet most teams prepare with scattered data and spreadsheets. Atlas gives quality teams 700,000+ inspections, 6,000+ investigator reports, and an AI copilot to turn reg
- [How Warning Letters Impact FDA Inspection Outcomes?](https://www.atlas-compliance.ai/blog/how-warning-letters-impact-fda-inspection-outcomes): FDA warning letters are public notices of regulatory non-compliance. They freeze new drug approvals, invite follow-up inspections, and damage reputation. This post covers the consequences and the CAPA-driven response that reduces long-term 
- [Why did the USA ban DeepSeek?](https://www.atlas-compliance.ai/blog/why-did-the-usa-ban-deepseek): In early 2025, New York banned DeepSeek, a Chinese AI assistant, from state government devices. Federal lawmakers followed. This post breaks down the national security concerns, the parallels with TikTok, and what the decision signals for f
- [FDA Guidelines for Medical Device Manufacturers](https://www.atlas-compliance.ai/blog/fdas-guidelines-for-medical-device-manufacturers): Medical device manufacturers have to navigate FDA device classification, 510(k) clearance, PMA, 21 CFR Part 820 (QSR), labeling and UDI requirements, and post-market surveillance. This post walks through each piece and the common compliance
- [Atlas Compliance FAQ: 10 Questions Quality Teams Ask Before They Buy](https://www.atlas-compliance.ai/blog/top-10-questions-about-atlas-compliance): Atlas Compliance is an FDA inspection and enforcement intelligence platform for pharma and medical device quality teams. Ten questions buyers ask before choosing it, answered directly: data coverage, freshness, customers, security, onboardi
- [AI Drug Development: FDA Releases Draft Guidance](https://www.atlas-compliance.ai/blog/ai-drug-development-fda-releases-draft-guidance): The FDA's January 2025 draft guidance, "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products," sets out a risk framework, disclosure requirements, and credibility stand
- [What are common mistakes to avoid during FDA inspections?](https://www.atlas-compliance.ai/blog/common-mistakes-companies-make-during-fda-inspections): FDA inspections expose weaknesses in documentation, training, CAPA follow-through, and transparency. This post covers eight of the most common mistakes quality teams make during inspections and the practical solutions that prevent them.
- [How to Access FDA Inspection Report Quickly?](https://www.atlas-compliance.ai/blog/how-to-access-fda-inspection-report-quickly): FDA inspection reports are often months behind on the FDA website and trapped in unsearchable PDFs. Atlas gives quality teams sub-second access to 700,000+ inspections since 2010, with advanced filters for investigator, CFR code, site type,
- [What Is Atlas Compliance, and How Does It Help Pharma and Medical Device Companies?](https://www.atlas-compliance.ai/blog/what-is-atlas-compliance): Atlas is a data-driven platform built for pharma and medical device quality teams. It covers 700,000+ FDA inspections since 2010, including 30,000+ Form 483s and 11,828 warning letters, all searchable in under a second with an AI copilot on
- [How to Address and Prevent FDA Form 483 Observations?](https://www.atlas-compliance.ai/blog/how-to-address-and-prevent-fda-form-483-observations): FDA Form 483 observations flag GMP non-compliance during inspections. Common issues involve equipment qualification, documentation, process validation, training, and facility controls. Prevent them through proactive management, internal aud
- [Unexo's Operations Questioned as FDA Lists 12 Compliance Issues](https://www.atlas-compliance.ai/blog/12-compliance-issues-identified-during-unexo-fda-inspection): Unexo, an over-the-counter drug manufacturer, faced FDA scrutiny during a two-week inspection in May 2024. Investigators Nicole Knowlton and Kellia Hicks documented 12 observations, from missing batch records to a hole in the ceiling of the

## Optional
- [Privacy Policy](https://www.atlas-compliance.ai/privacy): Privacy, data handling, and website usage information.
- [Terms of Service](https://www.atlas-compliance.ai/terms-of-service): Legal terms governing use of the website.